Children with inherited familial hypercholesterolemia may benefit from taking pravastatin. Familial hypercholesterolemia is the result of a mutation in a gene that normally helps control low-density lipoprotein (LDL) cholesterol levels. The Finnish study assessed the safety and effectiveness of pravastatin for 2 years in 30 participants (19 girls, 11 boys) aged 4 to 18 years with the condition. The participants were put on a diet low in fat, saturated fat, and cholesterol, supplemented with plant stanol or sterol esters, which prevent absorption of cholesterol in the small intestine. Of the participants, 17% had lipid deposits in their arteries at the study's onset, and 27% had deposits at 12 months.
The findings, reported recently in the Journal of Clinical Endocrinology and Metabolism, showed that participants who followed the low-fat diet experienced an 11% reduction in total cholesterol and a 13% decrease in LDL levels. Also, treatment with pravastatin (10-20 mg daily) steadily lowered total cholesterol and LDL cholesterol. After 24 months, total cholesterol levels fell by 26% and LDL dropped by 32%.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs